summari report sale ep beat street
expect increas organ sale growth ex-fx
ep growth outlook believ result gener good
sale growth acceler medic
devic report ep beat consensu
estim ep upsid vs model primarili
driven higher sale net incom partli off-set higher
opex tax rate organ sale growth came
adjust sell day differ adjust
remicad rebat sell day differ compani
rais organ sale growth guidanc
ep guidanc narrow
ex-fx growth actual increas
year guidanc impli organ
growth deceler due tougher
yr/yr comp believ underli busi momentum
remain posit estim organ
sale growth ep
sale growth guidanc increas rais
organ sale growth guidanc initi
rais midpoint rang repres
improv growth adjust
gross-to-net adjust sell day expect sale growth
improv consum medic devic busi
vs expect face tougher yr/yr
comp back half year compani see fx
tailwind benefit previous
manag expect report sale
previou guidanc continu
exclud impact potenti gener zytiga competit
model organ sale growth assum gener
zytiga entri follow expir stay
octob estim anima exit repres
growth headwind year
continu next page
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
compani prioriti stock list
compani data secur llc estim reuter
continu previou page
growth deceler due tougher comp pharma base organ sale
growth guidanc impli growth vs year expect growth
acceler consum medic devic vs would expect pharma growth slow
vs due tougher yr/yr comp pharma sale grew organ
would expect growth low- mid-singl digit rang vs
addit us gener tracleer competit potenti procrit competit possibl rebat accrual
year-end could becom headwind growth said view stack
basi growth pharma would pretti close around model assum
medic devic sale growth actual slow somewhat vs mostli surgeri
busi face competit pressur robot lesser extent vision
believ double-digit growth contact lens may sustain consum
forecast organ growth year partli driven relaunch
babi care brand us china india
ep growth outlook rais rang narrow due fx narrow ep guidanc rang
midpoint rang increas note
underli oper ep ex-fx guidanc actual increas
partli off-set reduct fx tailwind fact fx benefit
nearli currenc becom earn headwind cent year
rais ep estim penni
organ growth acceler busi report total revenu
organ growth latter ahead exclud impact remicad rebat
adjust differ sell day hospit medic devic busi estim
underli sale growth improv pharma sale beat
consensu estim organ growth acceler
adjust remicad rebat strong perform larg driven
immunolog stelara tremfya oncolog zytiga imbruvica franchis medic devic total
sale consensu miss estim organ growth
improv modestli vs adjust sell day
differ report consum sale miss consensu estim
partli due retail destock ahead babi care relaunch organ growth consum slow
stabl adjust destock impact
transit strike brazil
price target nc
price target impli cash ep base sum-of-the-part
analysi risk includ delay pipelin product unexpect delay deal integr unexpect
deterior industri
expect overal growth improv multipl tailwind recent acquisit start
contribut organ
johnson johnson world comprehens broadli base healthcar compani
consum pharmaceut medic devic market medic devic segment consist primarili
product cardiovascular orthoped surgic vision compani report sale
year-over-year organ basi
